Published in J Pharmacol Exp Ther on March 01, 2000
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release (2015) 1.17
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem (2012) 1.02
Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res (2005) 1.01
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A (2014) 1.00
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats. Pharmaceutics (2010) 0.93
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol (2015) 0.91
Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res Ther (2010) 0.91
Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives. Int J Nanomedicine (2012) 0.90
Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.88
Designer lipids for drug delivery: from heads to tails. J Control Release (2014) 0.88
Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release (2015) 0.86
Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery. Int J Nanomedicine (2012) 0.86
Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon. Int J Nanomedicine (2011) 0.85
Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomedicine (2012) 0.84
Factors influencing in vivo disposition of polymeric micelles on multiple administrations. ACS Med Chem Lett (2014) 0.82
Lipid-Based Nanocarriers for RNA Delivery. Curr Pharm Des (2015) 0.81
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
Using the Power of Organic Synthesis for Engineering the Interactions of Nanoparticles with Biological Systems. Nano Today (2016) 0.80
The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J Control Release (2015) 0.80
Assembly of bio-nanoparticles for double controlled drug release. PLoS One (2013) 0.80
Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J Control Release (2014) 0.80
Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus. Acta Biomater (2016) 0.79
Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs. Int J Nanomedicine (2015) 0.78
Drug carriers based on highly protein-resistant materials for prolonged in vivo circulation time. Regen Biomater (2015) 0.78
Pharmacokinetics and antitumor efficacy of DSPE-PEG2000 polymeric liposomes loaded with quercetin and temozolomide: Analysis of their effectiveness in enhancing the chemosensitization of drug-resistant glioma cells. Int J Mol Med (2016) 0.77
Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease. ACS Appl Mater Interfaces (2016) 0.77
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol Appl Pharmacol (2016) 0.76
Self-assembled 20-nm (64)Cu-micelles enhance accumulation in rat glioblastoma. J Control Release (2015) 0.76
Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Int J Nanomedicine (2013) 0.76
Tolerance-like innate immunity and spleen injury: a novel discovery via the weekly administrations and consecutive injections of PEGylated emulsions. Int J Nanomedicine (2014) 0.76
Lipid nanoparticles for gene delivery. Adv Genet (2014) 0.76
Recent trends of polymer mediated liposomal gene delivery system. Biomed Res Int (2014) 0.76
Drug Carriers: Not an Innocent Delivery Man. AAPS J (2015) 0.75
Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer. Nanomaterials (Basel) (2016) 0.75
Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. Front Immunol (2017) 0.75
Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice. World J Gastroenterol (2004) 0.75
Nanomedicines for renal disease: current status and future applications. Nat Rev Nephrol (2016) 0.75
Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med (2001) 2.32
Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest (1996) 2.03
The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med (2001) 1.89
Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood (2001) 1.88
A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol (2002) 1.81
Tumour-targeted nanomedicines: principles and practice. Br J Cancer (2008) 1.81
Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab (1995) 1.74
Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets (2009) 1.70
Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev (2001) 1.62
Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis (1993) 1.61
Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther (2001) 1.55
Treatment of eczema herpeticum with acyclovir. Arch Dermatol (1983) 1.52
Sensitive determination of circulating anodic antigen in Schistosoma mansoni infected individuals by an enzyme-linked immunosorbent assay using monoclonal antibodies. Am J Trop Med Hyg (1989) 1.52
Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer (2006) 1.50
Fas-FasL interactions modulate host defense against systemic Candida albicans infection. J Infect Dis (1999) 1.47
Radiolabeled interleukin-8: specific scintigraphic detection of infection within a few hours. J Nucl Med (2000) 1.46
An in vitro assay based on surface plasmon resonance to predict the in vivo circulation kinetics of liposomes. J Control Release (2011) 1.43
Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine. J Nucl Med (1991) 1.42
Scintigraphic detection of bone and joint infections with indium-111-labeled nonspecific polyclonal human immunoglobulin G. J Nucl Med (1990) 1.42
Biodistribution and kinetics of radiolabeled proteins in rats with focal infection. J Nucl Med (1992) 1.41
Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. Eur J Nucl Med (1995) 1.41
Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci U S A (1997) 1.35
Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta (1997) 1.35
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol (1997) 1.35
Imaging infection/inflammation in the new millennium. Eur J Nucl Med (2001) 1.34
Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum (2000) 1.32
Medium-dependent regulation of proteinase gene expression in Lactococcus lactis: control of transcription initiation by specific dipeptides. J Bacteriol (1995) 1.32
Imaging of cellular therapies. Adv Drug Deliv Rev (2010) 1.30
Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis (1993) 1.30
Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res (1999) 1.28
Technetium-99m-labeled chemotactic peptides in acute infection and sterile inflammation. J Nucl Med (1997) 1.26
An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol (2000) 1.23
The uptake mechanisms of inflammation- and infection-localizing agents. Eur J Nucl Med (1996) 1.23
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer (2008) 1.23
Positional specificity of saturated and unsaturated fatty acids in phosphatidic acid from rat liver. Biochim Biophys Acta (1969) 1.22
Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res (1999) 1.19
Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett (1995) 1.16
Controlled release of rhBMP-2 loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate cement composites in vivo. J Control Release (2005) 1.14
Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta (1993) 1.14
In vivo release of rhBMP-2 loaded porous calcium phosphate cement pretreated with albumin. J Mater Sci Mater Med (2006) 1.12
Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol (1998) 1.12
Reflex sympathetic dystrophy of the hand: an excessive inflammatory response? Pain (1993) 1.11
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
Molecular analysis of the mevalonate kinase gene in a cohort of patients with the hyper-igd and periodic fever syndrome: its application as a diagnostic tool. Ann Intern Med (2001) 1.11
Steric stabilization of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes mediates prolonged circulation and tumor targeting in mice. J Gene Med (2004) 1.10
Radioimmunotherapy and colorectal cancer. Br J Surg (2005) 1.10
Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis (2004) 1.09
Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis. Diabetologia (2012) 1.09
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther (2000) 1.08
Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogammaglobulinemia. Eur J Clin Microbiol Infect Dis (1992) 1.08
Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des (2004) 1.08
Differentiation of phospholipases A in mitochondria and lysosomes of rat liver. J Lipid Res (1969) 1.06
Absolute organ activity estimated by five different methods of background correction. J Nucl Med (1998) 1.06
In vitro growth factor release from injectable calcium phosphate cements containing gelatin microspheres. J Biomed Mater Res A (2009) 1.05
Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med (2001) 1.04
Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. Eur J Immunol (2001) 1.03
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother (2001) 1.03
The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother (1991) 1.02
Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages. Biochim Biophys Acta (1988) 1.02
Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res (1987) 1.01
Interaction of liposomes with Kupffer cells in vitro. Exp Cell Res (1984) 1.01
Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta (1999) 1.00
A novel method to label liposomes with 99mTc by the hydrazino nicotinyl derivative. J Nucl Med (1999) 0.99
Sterically stabilized liposomes labeled with indium-111 to image focal infection. J Nucl Med (1995) 0.99
Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 0.98
Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J Drug Target (2000) 0.98
In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst (2001) 0.98
Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm (2006) 0.98